People

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads. The company’s December 2023 profile identified Mao as Head of Chemistry, specializing in medicinal chemistry and linker-payload design.